共 50 条
- [31] A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With HypophosphatasiaJOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 374 - 374Dahir, KathrynDunn, DerekHasan, JawadShannon, AmyPan, Wei-Jian
- [32] A PHASE 1, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1850 IN ADULTS WITH HYPOPHOSPHATASIAAGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S43 - S44Dahir, K.Dunn, D.Mitter, S.Hasan, J.Shannon, A.Pan, W.
- [33] A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With HypophosphatasiaJOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 70 - 70Dahir, KathrynDunn, DerekHasan, JawadShannon, AmyPan, Wei-Jian
- [34] Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumorsANNALS OF ONCOLOGY, 2023, 34 : S649 - S649Papadopoulos, K. P.Call, J. A.Sen, S.Smith, D.van der Horst, E.
- [35] A PHASE 1, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1850 IN ADULTS WITH HYPOPHOSPHATASIAAGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S191 - S192Dahir, K.Dunn, D.Mitter, S.Hasan, J.Shannon, A.Pan, W.
- [36] A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Piha-Paul, Sarina AnneAmin, AlpeshKovacs, ChristinaMagley, AndreaDas Purkayastha, D.Zhuo, Ying
- [37] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Ullenhag, Gustav J.Yachnin, JeffreyCarneiro, AnaElison, EmmaCarlsson, MalinRussell, Charlotte AstridSmith, Karin Enell
- [38] A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumorsCANCER RESEARCH, 2024, 84 (07)Cheng, YingLisberg, AaronLemech, CharlotteAbed, AfafChaudhry, ArvindSchmidt, AndrewLu, XinZhu, ZhongyuanGu, WeiQiu, YangShi, RongZhang, Bin
- [39] Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Lee, Dae HoRoohullah, AflahCho, Byoung ChulLemech, Charlotte Rosede Souza, Paul L.Millward, MichaelChoi, Jun YoungPark, Kyung EuiLee, MinseonKim, YeongMunShin, YoungkeeHan, Ji-Youn
- [40] An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaONCOLOGIST, 2019, 24 (06): : 747 - E218El Dika, ImaneLim, Ho YeongYong, Wei PengLin, Chia-ChiYoon, Jung-HwanModiano, ManuelFreilich, BradleyChoi, Hye JinChao, Tsu-YiKelley, Robin K.Brown, JoanneKnox, JenniferRyoo, Baek-YeolYau, ThomasAbou-Alfa, Ghassan K.